The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study

NCT02390414 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 290

Last updated 2023-04-03

Study results available
· View outcomes & findings →

Summary

The purpose of this observational study is to compare overall survival in older adults with myelodysplastic syndromes (MDS) who receive reduced intensity conditioning hematopoietic stem cell transplant (RIC HSCT) versus those who do not receive HSCT.

Conditions

  • Myelodysplastic Syndromes (MDS)

Sponsors & Collaborators

Principal Investigators

  • Gregory A Abel, MD, MPH · Dana-Farber Cancer Institute

Eligibility

Min Age
60 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2020-09-30
Completion
2020-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02390414 on ClinicalTrials.gov